{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:09:14Z","timestamp":1769213354841,"version":"3.49.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,11,20]],"date-time":"2016-11-20T00:00:00Z","timestamp":1479600000000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Agile Pharmaceuticals"},{"name":"Abbvie Pharmaceuticals"},{"DOI":"10.13039\/501100000801","name":"Bayer Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ContraMed"},{"name":"Evofem Inc"},{"name":"HRA Pharma"},{"name":"Merck Pharmaceuticals"},{"name":"Teva Pharmaceuticals"},{"DOI":"10.13039\/100005974","name":"Population Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005974","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Health"},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obstetrics and Gynecology Clinics of North America"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ogc.2015.07.007","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T12:29:57Z","timestamp":1442406597000},"page":"683-698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?"],"prefix":"10.1016","volume":"42","author":[{"given":"Leo","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey T.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"29","key":"10.1016\/j.ogc.2015.07.007_bib1","first-page":"1","article-title":"Use of contraception in the United States: 1982-2008","author":"Mosher","year":"2010","journal-title":"Vital Health Stat 23"},{"issue":"23 Suppl 1","key":"10.1016\/j.ogc.2015.07.007_bib2","first-page":"I4","article-title":"The epidemiology of venous thromboembolism","volume":"107","author":"White","year":"2003","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ogc.2015.07.007_bib3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1161\/ATVBAHA.108.162545","article-title":"The epidemiology of venous thromboembolism in the community","volume":"28","author":"Heit","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.ogc.2015.07.007_bib4","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/j.amepre.2009.12.017","article-title":"Venous thromboembolism","volume":"38","author":"Beckman","year":"2010","journal-title":"Am J Prev Med"},{"issue":"10","key":"10.1016\/j.ogc.2015.07.007_bib5","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/archinte.165.10.1173","article-title":"Prospective evaluation of health-related quality of life in patients with deep venous thrombosis","volume":"165","author":"Kahn","year":"2005","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.ogc.2015.07.007_bib6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.contraception.2006.12.018","article-title":"Range of published estimates of venous thromboembolism incidence in young women","volume":"75","author":"Heinemann","year":"2007","journal-title":"Contraception"},{"issue":"24","key":"10.1016\/j.ogc.2015.07.007_bib7","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1056\/NEJMoa1111840","article-title":"Thrombotic stroke and myocardial infarction with hormonal contraception","volume":"366","author":"Lidegaard","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9026","key":"10.1016\/j.ogc.2015.07.007_bib8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(95)12393-8","article-title":"Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","volume":"348","year":"1996","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ogc.2015.07.007_bib9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.fertnstert.2006.11.206","article-title":"A\u00a0prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women","volume":"88","author":"Margolis","year":"2007","journal-title":"Fertil Steril"},{"issue":"3","key":"10.1016\/j.ogc.2015.07.007_bib10","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jfprhc-2013-100624","article-title":"Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism","volume":"39","author":"Bitzer","year":"2013","journal-title":"J\u00a0Fam Plann Reprod Health Care"},{"issue":"8990","key":"10.1016\/j.ogc.2015.07.007_bib11","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(95)91926-0","article-title":"Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","volume":"346","year":"1995","journal-title":"Lancet"},{"issue":"8990","key":"10.1016\/j.ogc.2015.07.007_bib12","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(95)91928-7","article-title":"Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components","volume":"346","author":"Jick","year":"1995","journal-title":"Lancet"},{"issue":"8990","key":"10.1016\/j.ogc.2015.07.007_bib13","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0140-6736(95)91929-5","article-title":"Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen","volume":"346","author":"Bloemenkamp","year":"1995","journal-title":"Lancet"},{"issue":"7023","key":"10.1016\/j.ogc.2015.07.007_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/bmj.312.7023.83","article-title":"Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women","volume":"312","author":"Spitzer","year":"1996","journal-title":"BMJ"},{"issue":"aug13 2","key":"10.1016\/j.ogc.2015.07.007_bib15","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"issue":"10\u201313","key":"10.1016\/j.ogc.2015.07.007_bib16","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.steroids.2003.08.003","article-title":"All progestins are not created equal","volume":"68","author":"Stanczyk","year":"2003","journal-title":"Steroids"},{"issue":"2","key":"10.1016\/j.ogc.2015.07.007_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1210\/er.2012-1008","article-title":"Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects","volume":"34","author":"Stanczyk","year":"2013","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.ogc.2015.07.007_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0010-7824(02)00476-6","article-title":"The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study","volume":"67","author":"Oral Contraceptive and Hemostasis Study Group","year":"2003","journal-title":"Contraception"},{"issue":"8935","key":"10.1016\/j.ogc.2015.07.007_bib19","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(94)90286-0","article-title":"Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation","volume":"344","author":"Vandenbroucke","year":"1994","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ogc.2015.07.007_bib20","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2003-04-1285","article-title":"Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial","volume":"103","author":"Kemmeren","year":"2004","journal-title":"Blood"},{"issue":"aug07 2","key":"10.1016\/j.ogc.2015.07.007_bib21","doi-asserted-by":"crossref","first-page":"e4944","DOI":"10.1136\/bmj.e4944","article-title":"Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis","volume":"345","author":"Mantha","year":"2012","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ogc.2015.07.007_bib22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1067\/mob.2001.109656","article-title":"The pharmacokinetics and efficacy of different estrogens are not equivalent","volume":"184","author":"Ansbacher","year":"2001","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.ogc.2015.07.007_bib23","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/CIRCULATIONAHA.106.642280","article-title":"Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER Study","volume":"115","author":"Canonico","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ogc.2015.07.007_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.thromres.2010.01.045","article-title":"Mechanisms of estrogen-induced venous thromboembolism","volume":"126","author":"Tchaikovski","year":"2010","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.ogc.2015.07.007_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.contraception.2008.04.004","article-title":"Sex hormone-binding globulin: not a surrogate marker for venous thromboembolism in women using oral contraceptives","volume":"78","author":"Stanczyk","year":"2008","journal-title":"Contraception"},{"issue":"6","key":"10.1016\/j.ogc.2015.07.007_bib26","first-page":"482","article-title":"Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?","volume":"81","author":"Odlind","year":"2002","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"7","key":"10.1016\/j.ogc.2015.07.007_bib27","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1600-0412.2012.01444.x","article-title":"Hormonal contraception and venous thromboembolism","volume":"91","author":"Lidegaard","year":"2012","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"06","key":"10.1016\/j.ogc.2015.07.007_bib28","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1055\/s-0032-1328876","article-title":"Obesity and hormonal contraception: safety and efficacy","volume":"30","author":"Edelman","year":"2012","journal-title":"Semin Reprod Med"},{"issue":"6","key":"10.1016\/j.ogc.2015.07.007_bib29","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.contraception.2009.08.001","article-title":"Contraceptive considerations in obese women","volume":"80","author":"Edelman","year":"2009","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.ogc.2015.07.007_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1783\/147118910790291037","article-title":"Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies","volume":"36","author":"Shapiro","year":"2010","journal-title":"J\u00a0Fam Plann Reprod Health Care"},{"issue":"5","key":"10.1016\/j.ogc.2015.07.007_bib31","doi-asserted-by":"crossref","first-page":"377.e1","DOI":"10.1016\/j.ajog.2012.08.007","article-title":"Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003\u20132008","volume":"207","author":"Okoroh","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ogc.2015.07.007_bib32","doi-asserted-by":"crossref","first-page":"E115","DOI":"10.1503\/cmaj.120677","article-title":"Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis","volume":"185","author":"Bird","year":"2013","journal-title":"Can Med Assoc J"},{"issue":"3","key":"10.1016\/j.ogc.2015.07.007_bib33","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1521-6934(03)00015-4","article-title":"Thrombophilias and gynaecology","volume":"17","author":"Bloemenkamp","year":"2003","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.ogc.2015.07.007_bib34","series-title":"Contraceptive technology","author":"Hatcher","year":"2008"},{"issue":"1","key":"10.1016\/j.ogc.2015.07.007_bib35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/asheducation-2013.1.457","article-title":"The diagnosis and treatment of venous thromboembolism","volume":"2013","author":"Wells","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.ogc.2015.07.007_bib36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0010-7824(97)00119-4","article-title":"First-time use of newer oral contraceptives and the risk of venous thromboembolism","volume":"56","author":"Suissa","year":"1997","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.ogc.2015.07.007_bib37","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.contraception.2006.12.019","article-title":"The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on Oral Contraceptives based on 142,475 women-years of observation","volume":"75","author":"Dinger","year":"2007","journal-title":"Contraception"},{"issue":"4","key":"10.1016\/j.ogc.2015.07.007_bib38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.contraception.2014.01.023","article-title":"Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives","volume":"89","author":"Dinger","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.ogc.2015.07.007_bib39","series-title":"A\u00a0clinical guide for contraception","author":"Speroff","year":"2010"},{"issue":"4","key":"10.1016\/j.ogc.2015.07.007_bib40","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/humrep\/15.4.817","article-title":"Recurrent use of newer oral contraceptives and the risk of venous thromboembolism","volume":"15","author":"Suissa","year":"2000","journal-title":"Hum Reprod"},{"issue":"6","key":"10.1016\/j.ogc.2015.07.007_bib41","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.contraception.2008.07.004","article-title":"Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis","volume":"78","author":"Jensen","year":"2008","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.ogc.2015.07.007_bib42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/(SICI)1099-1557(199609)5:5<285::AID-PDS236>3.0.CO;2-T","article-title":"Could preferential prescribing and referral behaviour of physicians explain the elevated thrombosis risk found to be associated with third generation oral contraceptives?","volume":"5","author":"Heinemann","year":"1996","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9173","key":"10.1016\/j.ogc.2015.07.007_bib43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(99)01257-X","article-title":"Venous thromboembolism among new users of different oral contraceptives","volume":"354","author":"Herings","year":"1999","journal-title":"Lancet"},{"issue":"3 Supplement","key":"10.1016\/j.ogc.2015.07.007_bib44","doi-asserted-by":"crossref","first-page":"s78","DOI":"10.1053\/ob.1998.v179.a92634","article-title":"Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany","volume":"179","author":"Farmer","year":"1998","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ogc.2015.07.007_bib45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0010-7824(96)00112-6","article-title":"The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research","volume":"54","author":"Lewis","year":"1996","journal-title":"Contraception"},{"issue":"9045","key":"10.1016\/j.ogc.2015.07.007_bib46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(96)07496-X","article-title":"Population-based study of risk of venous thromboembolism associated with various oral contraceptives","volume":"349","author":"Farmer","year":"1997","journal-title":"Lancet"},{"issue":"apr21 2","key":"10.1016\/j.ogc.2015.07.007_bib47","doi-asserted-by":"crossref","first-page":"d2151","DOI":"10.1136\/bmj.d2151","article-title":"Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data","volume":"342","author":"Jick","year":"2011","journal-title":"BMJ"},{"issue":"apr21 2","key":"10.1016\/j.ogc.2015.07.007_bib48","doi-asserted-by":"crossref","first-page":"d2139","DOI":"10.1136\/bmj.d2139","article-title":"Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database","volume":"342","author":"Parkin","year":"2011","journal-title":"BMJ"},{"issue":"aug13 2","key":"10.1016\/j.ogc.2015.07.007_bib49","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"339","author":"Van Hylckama Vlieg","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ogc.2015.07.007_bib50","unstructured":"Research C for DE and. Drug Safety and Availability - FDA drug safety communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm299305.htm. Accessed March 3, 2015."},{"issue":"3","key":"10.1016\/j.ogc.2015.07.007_bib51","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.contraception.2005.03.005","article-title":"Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive","volume":"72","author":"Van den Heuvel","year":"2005","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.ogc.2015.07.007_bib52","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.contraception.2007.03.003","article-title":"Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 \u03bcg of ethinyl estradiol","volume":"76","author":"Jick","year":"2007","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.ogc.2015.07.007_bib53","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.contraception.2009.07.004","article-title":"Postmarketing study of ORTHO EVRA\u00ae and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism","volume":"81","author":"Jick","year":"2010","journal-title":"Contraception"},{"issue":"3","key":"10.1016\/j.ogc.2015.07.007_bib54","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.contraception.2006.01.001","article-title":"Risk of nonfatal venous thromboembolism in\u00a0women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 \u03bcg of ethinyl estradiol","volume":"73","author":"Jick","year":"2006","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.ogc.2015.07.007_bib55","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.contraception.2009.12.009","article-title":"Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users","volume":"81","author":"Dore","year":"2010","journal-title":"Contraception"},{"issue":"2, Part 1","key":"10.1016\/j.ogc.2015.07.007_bib56","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/01.AOG.0000250968.82370.04","article-title":"Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users","volume":"109","author":"Cole","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ogc.2015.07.007_bib57","doi-asserted-by":"crossref","first-page":"e2990","DOI":"10.1136\/bmj.e2990","article-title":"Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10","volume":"344","author":"Lidegaard","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.ogc.2015.07.007_bib58","unstructured":"US Food and Drug Administration, Office of Surveillance and Epidemiology. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. Available at: www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM277384.pdf. Accessed May 21, 2015."},{"issue":"2 Pt 1","key":"10.1016\/j.ogc.2015.07.007_bib59","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/AOG.0b013e3181626d1b","article-title":"Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial","volume":"111","author":"Johnson","year":"2008","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.ogc.2015.07.007_bib60","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.contraception.2006.04.005","article-title":"Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins","volume":"74","author":"White","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.ogc.2015.07.007_bib61","series-title":"The Lancet handbook of essential concepts in clinical research","author":"Schulz","year":"2006"},{"issue":"4","key":"10.1016\/j.ogc.2015.07.007_bib62","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/AOG.0b013e3182a5ec6b","article-title":"Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring","volume":"122","author":"Dinger","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ogc.2015.07.007_bib63","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1783\/147118910791749425","article-title":"Oral Contraceptives and venous thromboembolism consensus opinion from an International Workshop held in Berlin, Germany in December 2009","volume":"36","author":"Reid","year":"2010","journal-title":"J\u00a0Fam Plann Reprod Health Care"},{"issue":"3","key":"10.1016\/j.ogc.2015.07.007_bib64","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.contraception.2010.04.006","article-title":"Factors affecting mortality in a large cohort study with special reference to oral contraceptive use","volume":"82","author":"Vessey","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.ogc.2015.07.007_bib65","unstructured":"WHO. Medical eligibility criteria for contraceptive use. WHO. Available at: http:\/\/www.who.int\/reproductivehealth\/publications\/family_planning\/9789241563888\/en\/. Accessed May 18, 2015."},{"key":"10.1016\/j.ogc.2015.07.007_bib66","unstructured":"CDC - United States medical eligibility criteria (USMEC) for contraceptive use - reproductive health. Available at: http:\/\/www.cdc.gov\/reproductivehealth\/unintendedpregnancy\/usmec.htm. Accessed July 28, 2014."}],"container-title":["Obstetrics and Gynecology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854515000789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854515000789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:15:43Z","timestamp":1760177743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889854515000789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0889854515000789"],"URL":"https:\/\/doi.org\/10.1016\/j.ogc.2015.07.007","relation":{},"ISSN":["0889-8545"],"issn-type":[{"value":"0889-8545","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?","name":"articletitle","label":"Article Title"},{"value":"Obstetrics and Gynecology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ogc.2015.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}